Compare Kenvue Inc. Common Stock (KVUE) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kenvue Inc. Common Stock vs Thomson Reuters Corp — how do they compare? Kenvue Inc. Common Stock trades at $17.7 (market cap $34.06B), while Thomson Reuters Corp trades at $103.21 (market cap $43.89B). The key difference: Thomson Reuters Corp is the larger of the two by market cap, and Kenvue Inc. Common Stock pays the higher dividend (4.74%). Which is the better fit depends on your goals.
| KVUE | TRI | |
|---|---|---|
Market Cap | $34.06B | $43.89B |
Volume | 23,267,228 | 1,648,199 |
Sector | Consumer Staples | Industrials |
52-Week High | $19.83 | $163.45 |
52-Week Low | $14.11 | $76.55 |
Enterprise Value | $41.56B | $46.51B |
Dividend Yield | 4.74% | 2.58% |
Typical Hold Time | — | 63 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Thomson Reuters (TRI) trades at $103.21, up 3.96% today, showing strong momentum near resistance at $103. The stock maintains robust fundamentals with 10% organic growth in core businesses and a 21.22% net income margin. Recent strategic moves include divesting the printing unit to focus on technology and launching a proprietary AI model, positioning for future growth. Technical indicators show bullish momentum with the current price approaching key resistance levels.
The outlook remains positive with analyst consensus targeting $133.25 (29% upside), supported by recurring revenue strength and AI expansion. Risks include cybersecurity incidents and execution challenges in tech transformation. With 52% of analysts rating Buy and strong institutional interest, TRI presents a growth opportunity tempered by valuation concerns at current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kenvue Inc. Common Stock
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
